Table 3 Statin use and risk of 5-year disease-specific mortality after esophagectomy for esophageal cancer (complete case analysis)

All patients

 No statins

635

221

1.00 (Reference)

1.00 (Reference)

 Statins

186

66

0.98 (0.75–1.30)

0.88 (0.64–1.23)

Age ≤ 59 years

 No statins

189

58

1.00 (Reference)

1.00 (Reference)

 Statins

31

6

0.47 (0.21–1.05)

0.48 (0.20–1.13)

Age 60–65 years

 No statins

154

61

1.00 (Reference)

1.00 (Reference)

 Statins

38

14

1.07 (0.62–1.84)

0.90 (0.48–1.67)

Age 66–71 years

 No statins

164

56

1.00 (Reference)

1.00 (Reference)

 Statins

65

23

0.98 (0.64–1.51)

0.96 (0.57–1.61)

Age ≥ 72 years

 No statins

128

46

1.00 (Reference)

1.00 (Reference)

 Statins

52

23

1.29 (0.84–1.98)

1.09 (0.64–1.87)

Men

 No statins

481

183

1.00 (Reference)

1.00 (Reference)

 Statins

164

59

0.99 (0.75–1.33)

0.86 (0.61–1.22)

Women

 No statins

154

38

1.00 (Reference)

1.00 (Reference)

 Statins

22

7

0.87 (0.41–1.85)

1.08 (0.47–2.48)

Tumor stage 0-I

 No statins

265

57

1.00 (Reference)

1.00 (Reference)

 Statins

76

13

0.41 (0.23–0.71)

0.70 (0.38–1.31)

Tumor stage II

 No statins

140

43

1.00 (Reference)

1.00 (Reference)

 Statins

42

20

1.34 (0.85–2.12)

1.51 (0.85–2.66)

Tumor stage III

 No statins

170

87

1.00 (Reference)

1.00 (Reference)

 Statins

58

29

1.66 (1.13–0.44)

0.80 (0.51–1.28)

Tumor stage IV

 No statins

60

34

1.00 (Reference)

1.00 (Reference)

 Statins

10

4

1.42 (0.53–3.82)

0.61 (0.21–1.78)

Adenocarcinoma

 No statins

464

153

1.00 (Reference)

1.00 (Reference)

 Statins

153

52

0.93 (0.69–1.26)

0.94 (0.66–1.35)

Squamous cell carcinoma

 No statins

171

68

1.00 (Reference)

1.00 (Reference)

 Statins

33

14

1.24 (0.72–2.12)

0.72 (0.39–1.34)